J&J, Vertex Partner To Commercialize VX-950 For Hepatitis C

J&J gains rights to the protease inhibitor in certain international markets with a $165 mil. up-front payment to Vertex.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet